|
WO2020014539A1
|
|
Methods and compositions for targeting cancer cells for treatment
|
|
CN111432858A
|
|
Drug infusion device, system and method
|
|
EP3773649A1
|
|
Personalized cancer vaccines
|
|
WO2019169389A1
|
|
Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors
|
|
CN112165937A
|
|
Methods and compositions for radioprotection using RRx-001
|
|
WO2019164593A2
|
|
Methods and compositions utilizing rrx-001 combination therapy for radioprotection
|
|
AU2018338612A1
|
|
Immunomodulatory fusion proteins
|
|
SG11201914046WA
|
|
Compositions for parenteral administration of therapeutic agents
|
|
WO2018218242A1
|
|
Methods and compositions for combination therapy
|
|
CA3064863A1
|
|
Recombinant adenoviruses carrying transgenes
|
|
AU2018271999A1
|
|
Anti-angiogenic adenovirus
|
|
WO2018204677A1
|
|
Oncolytic adenovirus formulation
|
|
KR20200006058A
|
|
Multiple transgene recombinant adenovirus
|
|
EP3610003A1
|
|
Method for producing recombinant virus
|
|
SG11201906973TA
|
|
Multiple transgene recombinant adenovirus
|
|
WO2018140970A1
|
|
Tumor selective tata-box and caat-box mutants
|
|
KR20190128619A
|
|
Sulfoxyalkyl organononitro and related compounds and pharmaceutical compositions for use in medicine
|
|
CN110546168A
|
|
Immunomodulatory fusion proteins
|
|
AU2017207304A1
|
|
Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
|
|
US9987270B1
|
|
Treatment of gliomas using organonitro compound combination therapy
|
